Search Results
Your search for early matches 10016 pages
Showing 2901 - 2950COVID-19 and Cancer: A Toxic Combination
COVID-19 has caused 475,000 deaths in America, disproportionately among communities of color, poverty, immigrants, and older age. It has exposed a variety of inequities within our health-care system. However, the patients at greatest risk of death from COVID-19 are those with cancer. While 1.8% of...
Genome-Edited Donor-Derived Anti-CD19 CAR T-Cell Therapy Is Active in B-Cell Acute Lymphoblastic Leukemia
Pooled results of two phase I studies, reported in The Lancet by Reuben Benjamin, MBBS, of the Department of Haematological Medicine, King’s College Hospital, London, and colleagues, indicate that the genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product...
Novel Approaches in Chronic Lymphocytic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic approaches in chronic lymphocytic leukemia (CLL). For full...
B-Cell and T-Cell Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...
How the COVID-19 Pandemic Can Help Improve Cancer Research
The ripple effects of the coronavirus pandemic have been felt in every area of health care. In our medical specialty, oncology, clinical trials of new treatments were upended by COVID-19. In the early months of the pandemic, widespread interruptions in trial enrollment prevented some patients...
One-Third of Cancer Survivors Reported Worry About Health-Care Disruptions Early in the COVID-19 Pandemic
A new study published by Corinne Leach, MPH, MS, PhD, and colleagues in the Journal of Psychosocial Oncology reported that early in the COVID-19 pandemic in the United States, one-third of cancer survivors worried about treatment and cancer care disruptions. Using a mixed-methods approach,...
Expert Point of View: Meredith Regan, ScD, and Sara Hurvitz, MD
In the San Antonio meeting’s closing session, “View From the Trenches: What Will You Do Monday Morning?” Meredith Regan, ScD, and Sara Hurvitz, MD, offered their thoughts on the use of RSClin in the clinic, as described at the San Antonio Breast Cancer Symposium by Joseph Sparano, MD.1 Dr. Regan...
Prognostic Tool RSClin Introduced for Early Breast Cancer
Data from the TAILORx study and several National Surgical Adjuvant Breast and Bowel Project (NSABP) trials have been used to develop a new prognostic tool, RSClin, which aims to individualize the estimate of recurrence risk in early breast cancer and to more accurately predict the risk-reduction...
Can Weight Loss During Treatment and Follow-up Affect Breast Cancer Outcomes?
Research published by Martel et al in JNCCN—Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for patients with HER2-positive early breast cancer—and found a 5% weight loss in patients over 2 years was associated with worse outcomes. Weight gain over the same...
Chemotherapy-Induced ‘Dormancy’ in AML Allows Cancer Cell Survival, May Contribute to Relapse
Researchers have identified a cellular resilience mechanism through which acute myeloid leukemia (AML) cells survive cancer treatment and repopulate, leading to disease relapse. The research, published by Cihangir Duy, PhD, MS, and colleagues in Cancer Discovery, also suggests that certain drugs...
Trends in Germline Genetic Testing in Women Diagnosed With Breast or Ovarian Cancer
In a study of germline genetic testing in women diagnosed with breast or ovarian cancer reported in the Journal of Clinical Oncology, Allison W. Kurian, MD, MSc, and colleagues found that undertesting persists in patients with ovarian cancer, and that most pathogenic variants are found in 20 breast ...
NEOSTAR: Neoadjuvant Nivolumab or Nivolumab/Ipilimumab in Operable NSCLC
The randomized phase II NEOSTAR trial, which examined single-agent and combined neoadjuvant immune checkpoint inhibitor therapy in patients with stage I to III non–small cell lung cancer (NSCLC), found combination therapy produced a significant clinical benefit (as assessed by major pathologic...
PET-Guided Omission of Consolidation Radiotherapy in Early-Stage Unfavorable Hodgkin Lymphoma
In a phase III German Hodgkin Study Group trial (GHSG HD17) reported in The Lancet Oncology, Peter Borchmann, MD, and colleagues found that positron-emission tomography (PET)-guided omission of consolidation radiotherapy was associated with noninferior progression-free survival among patients with...
Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome
Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response (VGPR) or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess...
Expert Point of View: Ajay K. Nooka, MD, MPH, FACP
Ajay K. Nooka, MD, MPH, FACP, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be...
New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma
B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging antibodies with novel targets are also achieving promising results. Studies presented at the 2020 American Society of Hematology (ASH) Annual...
Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL
Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s tyrosine kinase (BTK) inhibitors and BCL2...
Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies
Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to a study presented at the 2020...
ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased...
Study Finds Survival Disparities and Mutational Differences for Black Patients Younger Than 60 With AML
It has been well documented that, collectively, Black individuals have the highest death rates and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also have the highest cancer incidence.1 Although the causes of these inequities are complex and include...
ASH 2020 Meeting Highlights
The world of hematologic malignancies continues to move forward at a robust pace despite the challenges of the COVID era. Although some areas of clinical trials and basic research suffered short-term stoppages or delays due to the pandemic, the studies presented at the 2020 American Society of...
Comparison of Imaging Regimens for Stage I Seminoma After Orchiectomy
Men who have had treatment for early-stage testicular cancer may benefit from fewer monitoring scans, freeing them from some of the harmful radiation that comes from computerized tomography (CT) imaging, according to results from the phase III TRISST clinical trial presented by Joffe et al at the...
Addition of Adjuvant Pertuzumab to Chemotherapy Plus Trastuzumab in Early HER2-Positive Breast Cancer: 6-Year Follow-up of the APHINITY Trial
As reported in the Journal of Clinical Oncology by Martine Piccart, MD, PhD, and colleagues, the preplanned second interim analysis of overall survival in the phase III APHINITY trial showed no significant benefit of the addition of adjuvant pertuzumab to chemotherapy plus trastuzumab after a...
Joint ASCO/ACS CAN Letter: States Must Include Patients With Cancer on Their COVID-19 Vaccine Priority Lists
In the midst of growing concerns that patients with cancer have limited access to the COVID-19 vaccines, the Association for Clinical Oncology (ASCO) and American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society, issued a joint letter to every...
Addition of Primary Tumor Resection to Chemotherapy for Asymptomatic Primary Colorectal Cancer Tumors and Synchronous Unresectable Metastases
In a Japanese phase III trial (JCOG1007; iPACS) reported in the Journal of Clinical Oncology, Kanemitsu et al found that the addition of primary tumor resection to chemotherapy did not improve overall survival vs chemotherapy alone in patients with asymptomatic primary colorectal cancer tumors and...
Have Breast Cancer Mortality Rates Stopped Declining for Younger Women?
Breast cancer death rates have stopped declining for women in the United States younger than age 40, ending a trend that existed from 1987 to 2010, according to a report published by Hendrick et al in Radiology. Breast cancer is the most common nonskin cancer and the second most common cause of...
SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis
Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to updates from the SIMPLIFY-1 and SIMPLIFY-2 trials presented at the 2020 American Society of Hematology...
ASCO Advocates for Priority Status for Patients With Cancer in COVID-19 Vaccine Distribution Plans, Provides Information on Safety and Efficacy of Vaccinations
The American Society of Clinical Oncology and the Association for Clinical Oncology, collectively referred to as ASCO, understand the challenges faced by ASCO members and patients with cancer in dealing with the COVID-19 pandemic, in determining the best treatment for patients, and in addressing...
Chinese Society of Clinical Oncology and ASCO Approve First Joint Guideline for Treatment of Stage II to IVA Nasopharyngeal Carcinoma
The Chinese Society of Clinical Oncology (CSCO) and ASCO have approved a joint guideline for the treatment of stage II to IVA nasopharyngeal carcinoma.1 The guideline was drafted by a panel of Chinese and U.S. experts and provides, for the first time, a clear set of recommendations for the use of...
High-Risk Cutaneous Squamous Cell Carcinomas: The Present and Future
Cutaneous squamous cell carcinoma is the second most common type of skin cancer, with more than 1 million cases diagnosed in the United States annually.1 Historically, cutaneous squamous cell carcinoma is grouped together with basal cell carcinoma and collectively referred to as nonmelanoma skin...
Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also...
Novel Insights Into Multiple Myeloma
“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for...
COVID Virus–Specific T Cells: Potential Treatment of Severe COVID-19 Infection Under Study
It may be possible to exploit T cells from healthy volunteers who have recovered from COVID-19 as a treatment for this viral infection. Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine have designed an off-the-shelf COVID virus–specific T-cell product (called...
Expert Point of View: Neil M. Iyengar, MD
Neil M. Iyengar, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, has researched the links between breast cancer and lifestyle. He provided comments on these two abstracts from the 2020 San Antonio Breast Cancer Symposium (SABCS) for The ASCO Post. “These two...
ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
Expert Point of View: Michael J. Overman, MD
The study’s invited discussant, Michael J. Overman, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, said the findings of the study presented by Henriksen et al1 add to a convincing body of data showing that “the use of circulating...
Predicting Postoperative Recurrence in Stage I to III Colorectal Cancer With Circulating Tumor DNA
Patients with stage I to III colorectal cancer who have a high risk for recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA proved more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Benefits Survival in Cholangiocarcinoma
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Capivasertib for AKT1 E17K–Mutated Metastatic Cancers: NCI-MATCH Subprotocol EAY131-Y
As reported in JAMA Oncology by Kevin Kalinsky, MD, MS, and colleagues, the NCI-MATCH trial’s phase II subprotocol EAY131-Y has shown activity of the pan-AKT inhibitor capivasertib in a range of metastatic tumors with an AKT1 E17K mutation. The phase II trial enrolled 35 evaluable adult patients...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
The Lustgarten Foundation and AACR Honor Two American Icons by Establishing New Career Development Awards
The Lustgarten Foundation and the American Association for Cancer Research (AACR) have announced two new career development awards for early-career female and underrepresented pancreatic cancer researchers, representing a commitment of the Lustgarten Foundation of up to $1.8 million. The awards...
Improvement in Patient-Reported Outcomes After Stopping Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
In the prospective LAST study reported in JAMA Oncology, Ehab Atallah, MD, and Kathryn Flynn, PhD, of the Medical College of Wisconsin, Milwaukee, and colleagues, found that stopping tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) was associated with the...
Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79
Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature. “At St. Jude, the nature of our work requires a bold, ambitious...
Delay in Time Between Abnormal At-Home Screening and Colonoscopy May Increase Colorectal Cancer Risk
At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening. Usage of these tests has increased during the COVID-19 pandemic as patients try to avoid clinical visits. However, effectiveness of these screening tools, along with...
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
Patient-Reported Outcomes From the CROWN Trial: First-Line Lorlatinib vs Crizotinib for ALK-Positive NSCLC
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration in chest pain, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented at the International Association for the Study of...
Nivolumab Monotherapy Improves Survival in Patients With Relapsed Malignant Mesothelioma
In patients with relapsed malignant mesothelioma, treatment with single-agent nivolumab led to a significant improvement in both overall and progression-free survival in the phase III CONFIRM trial. These findings were presented by Dean A. Fennell, FRCP, PhD, Professor and Chair of Thoracic Medical ...
